Hyperuricemia and kidney damage in patients with cardiovascular disease: A review
- 作者: Mironova O.1
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 94, 编号 12 (2022)
- 页面: 1426-1430
- 栏目: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/144207
- DOI: https://doi.org/10.26442/00403660.2022.12.201999
- ID: 144207
如何引用文章
全文:
详细
Many studies have been conducted confirming the effect of uric acid (UA) on kidney function. It is obvious that there is a relationship between the effect of UA not only on kidney function, but also on the cardiovascular system, increasing cardiovascular risk. The review article provides basic information about the pathogenesis, principles and features of prescribing therapy to patients with chronic kidney disease (CKD) and cardiovascular disease. A lot of data currently indicates that hyperuricemia, both with and without crystal deposition, is associated with high cardiovascular risk and decreased kidney function. A number of studies and meta-analyses indicate that urate-reducing therapy prevents and slows down the decline in kidney function in patients with CKD, many of whom suffer from cardiovascular diseases or at least have several risk factors. Despite the fact that currently the guidelines for the treatment of CKD do not include a recommendation for the start of urate-lowering therapy, a large amount of data has been accumulated on the potential benefits of such treatment even in the absence of a diagnosis of gout. The preferred group of drugs for this group of patients are xanthine oxidase inhibitors, and for patients with eGFR below 30 ml/min/1.73 m2, it seems that allopurinol currently has larger evidence base for the efficacy and safety of prescribing.
作者简介
Olga Mironova
Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: mironova_o_yu@staff.sechenov.ru
ORCID iD: 0000-0002-5820-1759
д-р мед. наук, проф. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, Moscow参考
- Marangella M. Uric acid elimination in the urine. Pathophysiological implications. Contrib Nephrol. 2005;147:132-48. doi: 10.1159/000082551
- Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7-13. doi: 10.7326/0003-4819-131-1-199907060-00003
- Richette P, Perez-Ruiz F, Doherty M, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10:654-61. doi: 10.1038/nrrheum.2014.124
- Nashar K, Fried LF. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis. 2012;19:386-91. doi: 10.1053/j.ackd.2012.05.004
- Moe OW. Posing the question again: does chronic uric acid nephropathy exist? J Am Soc Nephrol. 2010;21:395-7. doi: 10.1681/ASN.2008101115
- Johnson RJ, Kang D-H, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertens (Dallas, Tex 1979). 2003;41:1183-90. doi: 10.1161/01.HYP.0000069700.62727.C5
- Berger L, Yü TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605-13. doi: 10.1016/0002-9343(75)90222-3
- Sato Y, Feig DI, Stack AG, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019;15:767-75. doi: 10.1038/s41581-019-0174-z
- Cheng D, Du R, Wu XY, et al. Serum Uric Acid is Associated with the Predicted Risk of Prevalent Cardiovascular Disease in a Community-dwelling Population without Diabetes. Biomed Environ Sci. 2018;31:106-14. doi: 10.3967/bes2018.013
- Desideri G, Virdis A, Casiglia E, et al. Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study. High Blood Press Cardiovasc Prev. 2018;25:197-202. doi: 10.1007/s40292-018-0250-7
- Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150-63. doi: 10.1016/j.cca.2018.05.046
- Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, et al. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2015;22:513-8. doi: 10.1177/2047487313519346
- Borghi C, Cicero AFG. Serum Uric Acid and Cardiometabolic Disease: Another Brick in the Wall? Hypertension (Dallas, Tex. 1979). 2017;69:1011-3. doi: 10.1161/HYPERTENSIONAHA.117.09081
- Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33:1729-41. doi: 10.1097/HJH.0000000000000701
- Gaita L, Timar R, Lupascu N, et al. The Impact Of Hyperuricemia On Cardiometabolic Risk Factors In Patients With Diabetes Mellitus: A Cross-Sectional Study. Diabetes Metab Syndr Obes. 2019;12:2003-10. doi: 10.2147/DMSO.S222570
- De Cosmo S, Viazzi F, Pacilli A, et al. Serum Uric Acid and Risk of CKD in Type 2 Diabetes. Clin J Am Soc Nephrol. 2015;10:1921-9. doi: 10.2215/CJN.03140315
- Feig DI, Madero M, Jalal DI, et al. Uric acid and the origins of hypertension. J Pediatr. 2013;162:896-902. doi: 10.1016/j.jpeds.2012.12.078
- Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:102-10. doi: 10.1002/acr.20344
- Zhang W, Sun K, Yang Y, et al. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem. 2009;55:2026-34. doi: 10.1373/clinchem.2009.124891
- Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307-15. doi: 10.2337/db12-1814
- Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737-42. doi: 10.2337/dc09-0288
- Lv Q, Meng X-F, He F-F, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One. 2013;8:e56864. doi: 10.1371/journal.pone.0056864
- Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertens (Dallas, Tex 1979). 2003;42:474-80. doi: 10.1161/01.HYP.0000091371.53502.D3
- Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: Which is chasing which? Nephrol Dial Transplant. 2013;28:2221-8. doi: 10.1093/ndt/gft029
- Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. doi: 10.1186/1471-2369-15-122
- Zhu P, Liu Y, Han L, et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One. 2014;9:e100801. doi: 10.1371/journal.pone.0100801
- Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant. 2010;25:1865-9. doi: 10.1093/ndt/gfp740
- Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes. 2009;58:1668-71. doi: 10.2337/db09-0014
- Kanbay M, Solak Y, Afsar B, et al. Serum Uric Acid and Risk for Acute Kidney Injury Following Contrast. Angiology. 2017;68:132-44. doi: 10.1177/0003319716644395
- Lapsia V, Johnson RJ, Dass B, et al. Elevated uric acid increases the risk for acute kidney injury. Am J Med. 2012;125:302.e9-17. doi: 10.1016/j.amjmed.2011.06.021
- Миронова О.Ю., Фомин В.В. Гиперурикемия у пациентов со стабильной ишемической болезнью сердца и артериальной гипертензией и чрескожные коронарные вмешательства. Consilium Medicum. 2020;22(12):20-2 [Mironova OI, Fomin V V. Hyperuricemia in patients with stable coronary artery disease and arterial hypertension and percutaneous coronary interventions. Consilium Medicum. 2020;22(12):20-2 (in Russian)]. doi: 10.26442/20751753.2020.12.200555
- Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62:170-80. doi: 10.1002/acr.20065
- Wheeler JG, Juzwishin KDM, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2:e76. doi: 10.1371/journal.pmed.0020076
- Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles. Am J Kidney Dis. 2010;56:247-50. doi: 10.1053/j.ajkd.2010.06.004
- Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertens (Dallas, Tex 1979). 2017;69:1036-44. doi: 10.1161/HYPERTENSIONAHA.116.08998
- Odden MC, Amadu A-R, Smit E, et al. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2002. Am J Kidney Dis. 2014;64:550-7. doi: 10.1053/j.ajkd.2014.04.024
- Garcia Puig J, Antón FM, Sanz AM, et al. Renal handling of uric acid in normal subjects by means of the pyrazinamide and probenecid tests. Nephron. 1983;35:183-6. doi: 10.1159/000183071
- Wu AH, Gladden JD, Ahmed M, et al. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4-7. doi: 10.1016/j.ijcard.2015.08.110
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104. doi: 10.1093/eurheartj/ehy339
- Чазова И.Е., Жернакова Ю.В., Кисляк О.А., и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022. Системные гипертензии. 2022;19(1):5-22 [Chazova IE, Zhernakova YuV, Kislyak OA. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5-22 (in Russian)]. doi: 10.38109/2075-082X-2022-1-5-22
- Xia X, Luo Q, Li B, et al. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2016;65:1326-41. doi: 10.1016/j.metabol.2016.05.009
- Bonino B, Leoncini G, Russo E, et al. Uric acid in CKD: has the jury come to the verdict? J Nephrol. 2020;33:715-24. doi: 10.1007/s40620-020-00702-7
- Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9:e026677. doi: 10.1136/bmjopen-2018-026677
- Kielstein JT, Pontremoli R, Burnier M. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Curr Hypertens Rep. 2020;22:102. doi: 10.1007/s11906-020-01116-3
- Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71:851-5. doi: 10.1053/j.ajkd.2017.12.009